WCG IPO Presentation Deck
WCG Expects to Grow Well in Excess of the Market
17
◆ Our Ethical Review segment is mandated by the FDA and generates significant and reoccurring revenue, representing approximately 52% (1) of our total revenue
◆ CTS provides the largest growth opportunity for new product development, cross-sell opportunities and acquisitions
◆ WCG has long-standing, industry leading relationships and contracts with research sites, providing a further competitive moat
14%
'21-23 TAM
Expected CAGR
Share Gains/
Cross-Sell
New Product
Development
Components of WCG Expected Growth
Acquisitions
20 - 25%
Expected Long-
Term Revenue
CAGR
Segment
Ethical Review
Clinical Trial
Solutions
(incl. M&A)
Source: Tufts CSDD, EvaluatePharma
Note: Long-term growth expectations are the Company's goals based on third-party TAM growth projections and should not be viewed as a guarantee of future
performance or guidance for any period. Actual results may differ and such differences may be material.
(1) Based on FY2020 revenue.
TAM
Expected
CAGR
2021-2023
13%
DNL
14%
wcg
WCG Long-
Term
Revenue
CAGR
14-16%
25-30%View entire presentation